French Observatory of Rare Malignant Tumors of the Ovary

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01304043
Recruitment Status : Completed
First Posted : February 25, 2011
Last Update Posted : April 20, 2012
Information provided by (Responsible Party):

Brief Summary:
To take charge of the treatment in rare adult ovarian tumors with an homogenous manner (germinal and sexual cords tumors), at different stages of the disease.

Condition or disease Intervention/treatment
Ovarian Tumors Drug: chemotherapies protocols

Detailed Description:
  • to establish prognosis factors for the disease
  • to proceed in a centralised examination of histologic laminas
  • to reach in the long-term and homogenous follow-up of the patients
  • to follow-up the long-term toxicities of the treatments given
  • to analyse and follow-up the later fertility of the patients
  • to evaluate the interest of setting a multi-disciplinary discussion forum on the Web

Study Type : Observational
Actual Enrollment : 204 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Observatoire Francophone Des Tumeurs Malignes Rares de l'Ovaire : Protocole de Prise en Charge Chez l'Adulte (Tumeurs Germinales et Des Cordons Sexuels)
Study Start Date : January 2002
Actual Study Completion Date : June 2011

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Ovarian Cancer
U.S. FDA Resources

Intervention Details:
    Drug: chemotherapies protocols
    Cisplatine 20 mg/m² IV Etoposide 100 mg/m² IV Bléomycine 30 mg IV

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
female with rare ovarian cancer

Inclusion Criteria:

  • age > 18 years old
  • germinal or sexual cords ovary tumors histologically proven
  • first line or relapse treatment
  • written informed consent

Exclusion Criteria:

  • mental ineptitude to understand and follow the study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01304043

Oncologie, Hôtel-Dieu, 1 place du parvis Notre-Dame
Paris, France, 75004
Sponsors and Collaborators
Principal Investigator: Isabelle Ray-Coquard, Physician GINECO

Additional Information:
Responsible Party: ARCAGY/ GINECO GROUP Identifier: NCT01304043     History of Changes
Other Study ID Numbers: TMRO
First Posted: February 25, 2011    Key Record Dates
Last Update Posted: April 20, 2012
Last Verified: April 2012

Keywords provided by ARCAGY/ GINECO GROUP:
ovarian tumors
rare ovarian tumors
germinal tumors
sexual cords tumors

Additional relevant MeSH terms:
Ovarian Neoplasms
Endocrine Gland Neoplasms
Neoplasms by Site
Ovarian Diseases
Adnexal Diseases
Genital Diseases, Female
Genital Neoplasms, Female
Urogenital Neoplasms
Endocrine System Diseases
Gonadal Disorders